COMP <GO>
BAX vs MRK // NET PROFIT MARGIN
Baxter International Inc. (NYSE) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: BAX 4
— MRK 10
▲ NET PROFIT MARGIN LEADER: MRK
LAST: $23.00 (-2.13%) • MKT CAP: $12.15B
net-margins
-8.50%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
net-margins
28.10%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BAX VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BAX | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 30.10% | 74.80% | -44.70 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -2.40% | 20.70% | -23.10 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 2.79% | 3.42% | -0.63 | MRK | /fcf-yield <GO> |
| Operating Margin | -2.70% | 34.30% | -37.00 | MRK | /operating-margins <GO> |
| Net Profit Margin ACTIVE | -8.50% | 28.10% | -36.60 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 5.70% | 1.30% | +4.40 | BAX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.86% | 2.26% | +0.60 | BAX | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.22 | 5.19 | -2.97 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 6.60% | +0.10 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 37.8 | 56.9 | -19.11 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 0.92 | +0.03 | BAX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 18.0x | 18.4x | -0.40 | BAX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $12.15B | $361.02B | -$348.87B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BAX REV | MRK REV | BAX GROSS % | MRK GROSS % | BAX FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $11.24B | $65.01B | 30.1% | 74.8% | $339.0M | $12.36B |
| FY 2024 | $10.64B | $64.17B | 37.5% | 76.3% | $540.4M | $18.10B |
| FY 2023 | $10.36B | $60.12B | 44.0% | 44.0% | $1.26B | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BAX // BETA 0.95
MRK // BETA 0.92